Protein level expression of Toll-like receptors 2, 4 and 9 in renal disease. by Batsford, S. et al.
Nephrol Dial Transplant (2011) 26: 1413–1416
doi: 10.1093/ndt/gfq752
Advance Access publication 10 January 2011
Preliminary communications
Protein level expression of Toll-like receptors 2, 4 and 9 in renal disease
Stephen Batsford1, Ursula Duermueller1, Christian Seemayer2, Christoph Mueller3, Helmut Hopfer1 and
Michael Mihatsch1
1Institute for Pathology, University Hospital Basel, Basel, Switzerland 2Institute of Pathology, Centre Hospitalier Universitaire
Vaudois, Lausanne, Switzerland and 3Institute of Pathology, University Bern, Bern, Switzerland
Correspondence and offprint requests to: Stephen Batsford; E-mail: stephen.batsford@uniklinik-freiburg.de
Abstract
Background. Toll-like receptors (TLR) recognize a variety
of ligands, including pathogen-associated molecular pat-
terns and link innate and adaptive immunity. Individual
receptors can be up-regulated during infection and inflam-
mation. We examined the expression of selected TLRs at
the protein level in various types of renal disease.
Methods. Frozen sections of renal biopsies were stained
with monoclonal antibodies to TLR-2, -4 and -9.
Results. Up-regulation of the three TLRs studied was seen,
although the extent was modest. TLR-2- and -4-positive
cells belonged to the population of infiltrating inflamma-
tory cells; only in the case of TLR-9 were intrinsic glomer-
ular cells positive in polyoma virus infection and haemolytic
uraemic syndrome (HUS).
Conclusions. Evidence for the involvement of the three
TLRs tested in a variety of human renal diseases was
found. These findings add to our understanding of the role
of the innate immune system in kidney disease.
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Introduction
The innate immune system possesses Toll-like receptors
(TLR) and this versatile receptor system senses invasion ofmi-
crobial pathogens. TLR recognize a variety of ligands, includ-
ing pathogen-associated molecular patterns (PAMP) and link
innate and adaptive immunity [1,2]. Mammalian TLRs com-
prise a large family of at least 11members. TLR-2 recognizes a
variety of microbial components, most prominent being di-
and tri-acyl lipopeptides [3]. TLR-4 is the essential long sought
receptor for lipopolysaccharide recognition [2]. TLR-9 recog-
nizes unmethylated CpG motifs in bacterial DNA [2]. Activa-
tion of innate immunity is a critical step in the development of
antigen-specific acquired immunity and individual receptors
can be up-regulated during infection and inflammation.
TLR up-regulation may be involved in renal disease [4]
and there is increasing data supporting a role for TLRs in
infectious autoimmune and inflammatory disorders of the
kidney [5].
We examined expression of selected TLRs at the protein
level in various types of renal disease; the range was re-
stricted by the limited availability of antibodies suitable for
immune histochemistry. Triggering receptors expressed by
myeloid cells (TREMs) activate myeloid cells, in particular
TREM1 triggers phagocytic secretion of pro-inflammatory
chemokines and cytokines amplifying inflammation in-
duced by microorganisms [6]. Since TLRs and TREMs
are believed to cooperate closely [6], the expression of
TREM1 in selected cases was also looked at.
Materials and methods
The classification and numbers of cases studied are listed in Table 1.
Frozen sections of renal biopsies were fixed in acetone for 10 min and
then stained with monoclonal antibodies to TLR-2 (clone TL2.3, diluted
1:50; Alexis ALX-804-324) and TLR-9 (clone 5G5, diluted 1:80; Serotec
MCA 2265) using the Vector ABC kit (VECTASTAIN AK-5000) and
TLR-4 (clone HTA 125, diluted 1:60; HyCult HM 2068) using the R.T.U.
VECASTAIN Universal Quick kit (PK 8800). All these antibodies have
been subjected to stringent specificity testing, including immunoprecipi-
tation and western blotting, as described in the suppliers’ data sheets (see
appropriate Web sites).
As positive control sections, frozen sections of Epstein-Barr virus-
infected tonsils were employed for TLR-2 and frozen sections of normal
placenta were used for TLR-4 and -9 (examples of positive and negative
controls for all antibodies shown as supplementary data).
As a negative control, the specific antibody was replaced with nonim-
mune mouse IgG2a (DAKO X0943) at the appropriate concentration.
Staining with all antibodies was also performed on sections from six
samples of normal human kidney. Sections were evaluated by two to three
observers independently.
Staining for TREM1 was performed with the anti TREM1 hybridoma
21C7 and the Vector ABC kit, as detailed above. A total of 10 renal biopsies
(5 positive and 5 negative for TLRs) were studied (polyoma nephropathy
n = 3, haemolytic uraemic syndrome (HUS) n = 2, M. Wegener n = 2,
interstitial rejection n = 2 and a single case of p-ANCA-positive GN).
Results
Antibodies to TLR-2, -4 and -9 did not produce noteworthy
staining on six different samples of normal human kidney.
The results obtained on 66 renal biopsy specimens from
© The Author 2011. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
selected renal diseases are shown in Table 1. Any unspe-
cific staining seen with the isotype control was taken into
account for the final judgment.
As can be seen in Table 1, TLR-2 and -4 were only seen
on infiltrating inflammatory cells (granulocytes/mono-
cytes), mainly in cases of HUS, M. Wegener, Polyoma
virus nephropathy (PVN) (Figure 1) and p-ANCA GN
(Figure 2); TLR-4 was more frequently positive than
TLR-2 and intrinsic renal cells were always negative.
TLR-9 was, with a single exception, seen only on glo-
merular cells (probably mesangial/podocytes) in four of
eight cases (50%) of HUS (Figure 3) and 2/12 (17%) cases
of PVN. Further pictures from the various disease entities
studied are shown in the supplementary data. An example
of unspecific tubular staining in a negative control is shown
in Figure 4.
In the 10 cases studied, staining for TREM1 was nega-
tive, and weak staining of tubular structures was considered
to be unspecific. For this reason, the series was not
extended.
Conclusions
Positive results were most often found in cases of polyoma
virus nephropathy, HUS and M. Wegener. TLR-2 and
-4-positive cells belonged to the population of infiltrating
inflammatory cells, which were often sparsely distributed;
only in the case of TLR-9 were intrinsic glomerular cells
positive in polyoma virus infection and HUS. These
findings may reflect aetiopathogenetic mechanisms; for
Table 1. Results of staining for TLR-2, -4 and -9 in selected renal diseases
Classification (n)
Native (N),
transplant
(Tx) TLR-2 TLR-4 TLR-9
HUS (8) N 1/8
Interstitial
infiltrate
3/8
Interstitial
infiltrate
4/8 Glomerular
mesangium/
podocytes
M. Wegener (c-ANCA
pos.) (6)
N 3/6
Interstitial
infiltrate
4/6
Interstitial
infiltrate
1/6
Interstitial
infiltrate
Postinfectious GN (4) N neg 2/4
Interstitial
infiltrate
neg
p-ANCA GN (6) N neg 5/6
Interstitial
infiltrate
neg
Acute interstitial nephritis (3) N neg neg neg
IgA-GN (3) N neg neg neg
Membranous GN (3) N neg neg neg
Polyoma virus nephropathy
(12)
Tx 1/12
Interstitial
infiltrate
10/12 Interstitial
infiltrate
2/12 Glomerular
mesangium/
podocytes
Interstitial rejection HLADR
neg/posa (6/6)
Tx neg neg 4/6 pos 2/6
interstitial
infiltrate
neg
Vascular rejection C4d
neg/posa (3/3)
Tx neg neg 2/3 pos 2/3
interstitial
infiltrate
neg
CIN toxicity (3) Tx neg neg neg
aNo obvious difference between positive and negative cases. neg, negative; pos, positive.
Fig. 1. TLR2: PVN with minor mononuclear/histiocytic infiltrates around
affected tubules, tubular epithelium and glomeruli are negative.
Fig. 2. TLR-4: p-ANCA-associated glomerulonephritis with dense focal
histiocytic infiltrates around tubules, tubular epithelium completely
negative.
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example, infections have long been thought to be involved
in cases of Wegener’s disease and HUS [7,8].
Little is known about innate immunity and polyoma
virus infection, a serious problem in renal transplantation.
Our finding of up-regulation of TLR-2, -4 and -9 in some
cases is intriguing; it possibly marks efforts to control viral
replication. A recent study in mice found that the TLR
signalling adapter protein MyD88 is involved in the devel-
opment of humoral immunity to polyoma virus [9]. More
intensive studies of innate immune mechanisms in polyo-
ma virus infections are clearly warranted.
Renal TLR expression has been studied by many inves-
tigators, mostly at the messenger RNA expression level
[10]. However, most of these studies were done on samples
of renal tissue compartments [11] and therefore contribu-
tions of infiltrating and intrinsic cells cannot be differen-
tiated. TLR-2, but not TLR-4 expression in tubules from
renal graft recipients, has been reported using immuno-
histochemistry [12]. Another study demonstrated TLR-4
expression in renal tubules in cases of cyclosporine
nephrotoxicity [13]. TLR-9 expression was found in lupus
nephritis, both tubulointerstitial and glomerular [14] or
only tubulointerstitial [15]. Cases of lupus nephritis were
not included in the current study. Using the protocols
employed here, we were unable to detect specific staining
for TLR-2, -4 or -9 on six different samples of normal
human kidney. Constitutive expression of TLR-2, -4 and
-9 at the protein level in normal human renal tissue
appears to be below the level of immunohistochemical de-
tection with the techniques employed. In our hands, diffuse
tubulointerstitial staining patterns had to be classified as
unspecific on the basis of stringent negative isotype con-
trols. Three of the studies cited above [12,13,15] employed
formalin-fixed paraffin-embedded tissue, only one used
frozen sections [14]. Furthermore, negative controls con-
sisted simply of omitting the primary antibody, more strin-
gent isotype controls were not included. This raises the
question whether differences in technical approaches
might, at least in part, help explain conflicting results?
Preliminary studies did not produce evidence of TREM1
expression in the renal diseases studied.
TLR-2 has been detected in normal mouse glomeruli and
tubules [16], revealing differences between species. Animal
models have provided evidence of TLR involvement in the
pathogenesis of some forms of experimental renal disease
[17,18]. TLR-2 expression on cultured proximal tubular cells
was stimulated by leptospiral outer membrane proteins [19],
TLR-4 has been linked to acute renal failure after sepsis [20]
and the TLR ligand CpG-DNA can aggravate immune com-
plex GN [21,22]. These effects were species specific; it
should be noted that in most animal studies, TLR-2 and -4
were expressed intrinsically on renal tubular cells and
TLR-9 was expressed mainly on infiltrating antigen pre-
senting cells (APC), rather the opposite to the situation
found in our studies in human biopsy material.
Further studies to elucidate the role of the innate
immune system in renal injury are clearly necessary.
Supplementary data
Supplementary data is available online at http://ndt.
oxfordjournals.org.
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Abstract
Background. Leflunomide (LEF)-induced interstitial lung
disease (ILD) has been reported in patients with rheuma-
toid arthritis. In China, LEF is used off-label for the treat-
ment of nephropathy.
Methods. Systemic review of the Chinese literature from
1999 to June 2010 for case reports and case series of LEF-
induced ILD in nephropathy patients.
Results. We identified seven cases of LEF-induced ILD
(three males and four females), with an average age of 45.9
years (range: 9–69 years). Six cases had primary nephrotic
syndrome and one had Henoch–Schoenlein purpura. Four
cases had diagnoses of renal pathology. Five patients were
given loading doses of LEF, followed by a maintenance dose
of 10–30 mg/day. The mean duration of LEF use was 62.9 ±
33.0 days (range: 20–120 days). The mean accumulated dose
of LEF was 1192.5 mg (range: 830–1800 mg). LEF therapy
was considered effective in four patients. Four patients died
(57.1%), three of whom had developed fevers. All three male
patients died and both of the young patients died. The mean
duration of LEF treatment was 83 days for patients who died
and 37 days for survivors.
Conclusions. LEF-induced ILD in patients with nephropathy
usually occurred after∼2months of treatment and an accumu-
lated dose of 1192.5mg.Duration ofLEFuse,male sex, young
age and fever seemed to increase the risk of mortality.
Keywords: glomerulonephritis; immnunosuppresant; interstitial lung
disease; leflunomide; pheumonitis
Introduction
Leflunomide (LEF) is an isoxazole derivative with anti-in-
flammatory and immunomodulating activities. It has been
available in >70 countries for >10 years and is one of the
1416 W.-x. Zhang et al.
© The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
